Omega Diagnostics, a medical testing company, has reported greater interim losses despite an increase in revenues.
Omega Diagnostics is confident that it can stem losses as the sales momentum increases
Omega Diagnostics Gp (ODX.L) Half-year Report
INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2021
Omega Diagnostics Gp (ODX.L) Notice of Results and Investor Presentation
Omega (AIM: ODX), the specialist medical diagnostics company focused on industry-leading Global Health (CD4 and COVID-19) and Health and Nutrition products, announces it will release its interim results for the
Omega Diagnostics Gp (ODX.L) Update on CTDA Regulations
Omega (AIM: ODX), the specialist medical diagnostics company focused on industry-leading Global Health (CD4 and COVID-19) and Health and Nutrition products, notes the UK Health Security Agency’s Medical Devices (Coronavirus
Omega Diagnostics Gp (ODX.L) Partnership with DAM Health and initial LFT order
Agreement for Omega’s Market Leading, UK Manufactured VISITECT ® COVID-19 Antigen LFT
Destiny Pharma PLC (DEST.L) Study gives strong support for potential of XF-73 & CEO Interview
Major US hospital-based clinical trial highlights benefit of nasal decolonization to reduce ICU infections caused by Staphylococcus aureus
Omega Diagnostics Gp (ODX.L) AGM Statement
Omega (AIM: ODX), the medical diagnostics company focused on Global Health (CD4 and COVID-19) and Health and Nutrition, will hold its Annual General Meeting (‘AGM’) today at 11am at Omega
Omega Diagnostics Gp (ODX.L) VISITECT ® COVID-19 antigen test self-test submission update
All supporting data and documentation now submitted to Omega’s European Notified Body
OKYO Pharma LTD (OKYO.L) Announces final audited results for the year ended 31 March 2021
LONDON, Aug. 02, 2021 (GLOBE NEWSWIRE) — OKYO Pharma Limited (the “Company”) is pleased to announce its final audited results for the year ended 31 March 2021.
Omega Diagnostics Gp (ODX.L) Posting of Annual Report & Accounts & Notice of AGM
Omega (AIM: ODX), the medical diagnostics company focused on Global Health (CD4 and COVID-19) and Health and Nutrition, announces that the Notice of Annual General Meeting (‘AGM’).
Sareum Holdings PLC (SAR.L) US Patent Notice of Allowance for SDC-1802
Cambridge, UK, 30 July 2021 – Sareum Holdings plc (AIM: SAR), the specialist drug development company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune diseases.
